Oxidative stress regulates left ventricular PDE5 expression in the failing heart
about
The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic HistoryPulmonary hypertension in patients with heart failure and preserved ejection fraction: differential diagnosis and managementThe pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertensionTherapeutic potential of PDE modulation in treating heart diseasePhosphodiesterases and cardiac cGMP: evolving roles and controversiesInhibition of type 5 phosphodiesterase counteracts β2-adrenergic signalling in beating cardiomyocytesDimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginineThe emperor's new clothes: PDE5 and the heartPhosphodiesterase type 5 inhibition may reduce diastolic function in women with ischemia but no obstructive coronary artery disease.Endoplasmic reticulum stress sensor protein kinase R-like endoplasmic reticulum kinase (PERK) protects against pressure overload-induced heart failure and lung remodeling.Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy.Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy.Reduced cardiac fructose 2,6 bisphosphate increases hypertrophy and decreases glycolysis following aortic constrictionConserved expression and functions of PDE4 in rodent and human heart.Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodelingKnockdown of Akt1 promotes Akt2 upregulation and resistance to oxidative-stress-induced apoptosis through control of multiple signaling pathwaysThe role of phosphodiesterase inhibitors in the management of pulmonary vascular diseasesExacerbated pulmonary arterial hypertension and right ventricular hypertrophy in animals with loss of function of extracellular superoxide dismutase.AMP activated protein kinase-α2 regulates expression of estrogen-related receptor-α, a metabolic transcription factor related to heart failure development.Differential expression of PDE5 in failing and nonfailing human myocardiumMineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice.Brief hyperoxia increases mitochondrial oxidation and increases phosphodiesterase 5 activity in fetal pulmonary artery smooth muscle cells.Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: heart failure causes severe lung diseaseCardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials.Evaluating oxidative stress in human cardiovascular disease: methodological aspects and considerations.Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling.Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.Phosphodiesterase type 5 inhibitors: back and forward from cardiac indicationsBest Practice BioBanking of Human Heart TissueAntagonism of the thromboxane-prostanoid receptor is cardioprotective against right ventricular pressure overload.The effects of long-term administration of tadalafil on STZ-induced diabetic rats with erectile dysfunction via a local antioxidative mechanismTadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.Effect of asymmetric dimethylarginine (ADMA) on heart failure development.Chronic inhibition of cGMP-specific phosphodiesterase 5 suppresses endoplasmic reticulum stress in heart failure.Chemotherapeutic efficacy of phosphodiesterase inhibitors in chagasic cardiomyopathy.Loss of the eukaryotic initiation factor 2α kinase general control nonderepressible 2 protects mice from pressure overload-induced congestive heart failure without affecting ventricular hypertrophy.The NO/ONOO-cycle as the central cause of heart failure.Double-stranded RNA-dependent protein kinase deficiency protects the heart from systolic overload-induced congestive heart failure.Modulating the nitric oxide - cyclic GMP pathway in the pressure-overloaded left ventricle and group II pulmonary hypertension.Developments in heart failure 2010.
P2860
Q26741387-A39ECC66-B4A8-456C-9D9F-30C0F9651730Q26750994-F7817D4D-32A8-4DAD-86EE-E732A2EE23E6Q26852171-0216E074-B83D-4C8B-A5C9-2FEE410F4533Q27005761-B3EFBE35-C277-4EA1-8C54-20560C245F2DQ27692588-C732F9EA-8FA8-498D-BB13-3F1378CC2063Q27967859-188F7DF6-BA46-4D1B-A81B-87BD71C214EEQ28506246-5F9F775A-6D19-4B5B-B825-6F8E552EF73BQ28543897-297AA951-92FF-4B4C-98DB-C4521D9C343BQ33711368-5ED54CBE-187F-4833-8509-1E98F18A183DQ34173536-8623416A-8663-4381-AC5C-E73A4A4E4B9BQ34279254-7B91FD82-3F24-4FCA-B0BD-BAF90207DC3DQ34315276-7190E040-F420-4DDC-8F72-BC8AE72C1729Q34545425-0E7AE109-40F6-40EF-9732-509CBCC4F1F7Q34548139-0F788E6A-7AA5-449E-97A3-72BF25B3568FQ34634339-6B3CC6CF-F157-443D-B27A-0F0B36EB7E96Q35031186-CDDB4E55-5773-4F27-A033-322DA3FFA9E6Q35156618-D2054C0F-D644-4220-9D93-D85FC9007DAAQ35205619-C0175C94-812D-43DC-AA3D-9CE42BA50313Q35238018-0763C3FA-BC59-4B30-866F-08C29EF2149EQ35680934-A024D2D1-43F7-4224-9976-2A101BCF7FFAQ36000073-820CDD57-4ECA-44ED-87D3-87E44EA1C79AQ36001831-5871BAF4-5E6A-4FA5-A25B-2FAA2D750930Q36108598-49DE170B-5E37-4636-A329-73EDAF79A94EQ36128551-07BFFA0A-4611-4733-B773-2A12CC8FF4C7Q36141348-3380125E-1081-474B-937A-92F8E8C00CF5Q36191580-360D6669-357C-4AAD-B47C-3856DD72B4B5Q36270020-21F970E1-CD47-485B-9729-D31E0F180E8CQ36460566-49AC23CB-37A7-45DC-84D0-C7FC621F69CFQ36688868-A734E427-19FF-42D9-AA01-54F25AB2CAE1Q36908852-FC369B4E-55D1-45D4-962D-C99C797E571AQ37037569-A8BF0299-420A-4E72-A83F-0C05C0017441Q37240478-78992940-78FC-4921-8029-64165E1F402AQ37245523-790B5B59-6B17-4AEE-8D61-D78F4E75C8FDQ37337837-DD538C9E-BB23-4B27-BF91-F27AEEAFF7CAQ37341337-1243FE98-2BFD-4775-AF3E-DC8EDE17D16AQ37365394-324C39C6-13E3-4830-BBFB-DF3B44DCCF18Q37375441-690D4F69-3F7C-41D5-A066-AEB540E3C341Q37678632-56BA31C1-ADEB-4464-AFD8-13280A3C261AQ37799652-99241D82-25D1-4001-85D7-AE8CEC43BB0FQ37859431-7839A6CE-0945-4E11-869E-85571C5F8E49
P2860
Oxidative stress regulates left ventricular PDE5 expression in the failing heart
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Oxidative stress regulates left ventricular PDE5 expression in the failing heart
@ast
Oxidative stress regulates left ventricular PDE5 expression in the failing heart
@en
Oxidative stress regulates left ventricular PDE5 expression in the failing heart
@nl
type
label
Oxidative stress regulates left ventricular PDE5 expression in the failing heart
@ast
Oxidative stress regulates left ventricular PDE5 expression in the failing heart
@en
Oxidative stress regulates left ventricular PDE5 expression in the failing heart
@nl
prefLabel
Oxidative stress regulates left ventricular PDE5 expression in the failing heart
@ast
Oxidative stress regulates left ventricular PDE5 expression in the failing heart
@en
Oxidative stress regulates left ventricular PDE5 expression in the failing heart
@nl
P2093
P2860
P50
P1433
P1476
Oxidative stress regulates left ventricular PDE5 expression in the failing heart
@en
P2093
Cris dos Remedios
Daniel J Garry
Guangshuo Zhu
Jay H Traverse
Jennifer L Hall
Marc Pritzker
Ping Zhang
Sangjin Lee
P2860
P304
P356
10.1161/CIRCULATIONAHA.109.906818
P407
P577
2010-03-22T00:00:00Z